Accessibility Menu
Cyclopharm logo

Cyclopharm(ASX) CYC

Market CapA$65.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-68%
5 Year-68%
1 Year-45%
1 Month+7%
A$0.52
-0.96%
-0.01Today
Cyclopharm last closing stock price
MetricPriceDate
Last closeAUD 0.522026-08-13
Cyclopharm stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.31%AUD 0.562026-08-06
1 month+7.22%AUD 0.492026-07-14
3 month-35.4%AUD 0.812026-05-15
Year to date-46.94%AUD 0.982025-12-30
1 year-45.26%AUD 0.952025-08-13
3 year-77.83%AUD 2.352023-08-14
5 year-68.49%AUD 1.652021-08-13
Since inception-67.7%AUD 1.612007-01-18

Cyclopharm Financials at a Glance

Market Cap

A$65.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$58.97M

Net Income (TTM)

-A$30.42M

EPS (TTM)

-A$0.16

P/E Ratio

-3.35

Dividend

A$0.00

Beta (Volatility)

0.06 (Low)

Price

A$0.52

Volume

272,432

Open

A$0.53

Previous Close

A$0.52

Daily Range

A$0.50 - A$0.53

52-Week Range

A$0.45 - A$1.29

Estimated Earnings Date

Aug 17, 2026

CYC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cyclopharm

Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals. The company operates primarily in the Asia Pacific, Europe, and Canada, focusing on innovative solutions for nuclear medicine.

Products and Services
  • Technegas diagnostic apparatus for pulmonary embolism detection
  • Advanced radiopharmaceutical agents for cancer and neurological disorders
  • Distribution of third-party diagnostic imaging products
Growth Outlook
  • Recent revenue growth of 9.5% in Q2 2025 compared to Q1 2025
  • Expansion into new markets expected to drive future sales
  • Investment in R&D to enhance product offerings and market competitiveness
Financial Highlights
  • Q2 2025 revenue of AUD 15.4 million, up from AUD 14.3 million in Q1 2025
  • Trailing twelve months (TTM) gross profit margin at 24.1%
  • Current ratio of 2.53 indicates strong short-term financial health
AI Generated • Jul 30, 2026

Industry

Healthcare Equipment and Supplies

Employees

109

CEO

James M. McBrayer

Headquarters

Kingsgrove, NSW 2208, AU

CYC Financials

Key Financial Metrics (TTM)

Gross Margin

24.11%

Operating Margin

-56.36%

Net Income Margin

-53.27%

Return on Equity

-54.48%

Return on Capital

-43.26%

Return on Assets

-37.35%

Earnings Yield

-29.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$65.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

125.73M

Volume

272.43K

Avg. Volume

145.27K

Financials (TTM)

Gross Profit

A$16.35M

Operating Income

-A$40.89M

EBITDA

-A$29.99M

Operating Cash Flow

-A$29.90M

Capital Expenditure

-A$2.87M

Free Cash Flow

-A$32.78M

Cash & ST Invst.

A$6.63M

Total Debt

A$14.92M

Cyclopharm Performance Analysis

Cyclopharm annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 23,218,79731.1%
20232023-12-31AUD 26,339,38913.4%
20242024-12-31AUD 27,572,5814.7%
20252025-12-31AUD 32,325,25617.2%
Cyclopharm sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3015.6%
Q42024-12-3117.0%
Q22025-06-307.4%
Q42025-12-319.6%
Cyclopharm annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.0727.4%
20232023-12-31AUD -0.05-29.3%
20242024-12-31AUD -0.13152.9%
20252025-12-31AUD -0.1622.0%
Cyclopharm sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-307.8%
Q42024-12-3134.0%
Q22025-06-30-34.6%
Q42025-12-31-24.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$16.90M

+59.2%

Gross Profit

-A$462.21K

+50.3%

Gross Margin

-2.73%

N/A

Market Cap

A$65.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$599.83K

N/A

Employees

109

N/A

Net Income

-A$9.53M

-427.9%

EBITDA

-A$8.48M

-791.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$6.63M

-43.5%

Total Debt

A$14.92M

+253.0%

Accounts Receivable

A$8.59M

+8.8%

Inventory

A$11.43M

+13.0%

Long Term Debt

A$14.36M

+257.8%

Short Term Debt

A$561.17K

+30.8%

Return on Assets

-37.35%

N/A

Return on Invested Capital

-52.30%

N/A

Free Cash Flow

-A$11.62M

-90.2%

Operating Cash Flow

-A$9.83M

-69.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
M7T.AXMach7 Technologies Limited
A$0.28-1.79%
ATX.AXAmplia Therapeutics Limited
A$0.15+0.00%
MVP.AXMedical Developments International Limited
A$0.45-3.26%
CMP.AXCompumedics Limited
A$0.23+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About CYC

What is the current price of Cyclopharm?

Cyclopharm is trading at A$0.52 per share.

What is the 52-week range for Cyclopharm?

Over the past 52 weeks, Cyclopharm has traded between A$0.45 and A$1.29.

How much debt does Cyclopharm have?

As of the most recent reporting period, Cyclopharm reported total debt of A$7.74M.

How much cash does Cyclopharm have on hand?

Cyclopharm reported A$6.63M in cash and cash equivalents in its most recent financial results.

What is Cyclopharm’s dividend yield?

Cyclopharm does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.